骨髓增生异常症候群 (MDS) 药物市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023 年，全球骨髓增生异常症候群(MDS) 药物市值为28 亿美元，预计2024 年至2032 年复合年增长率为8%。在老化人口中，导致对有效治疗的需求增加。例如，美国癌症协会报告称，美国每年诊断出约 10,000 例新的 MDS 病例，其中主要是 60 岁以上的个体。此外，诊断技术的进步促进了MDS的早期检测，为及时有效的治疗铺平了道路。这反过来又增加了对 MDS 药物的需求。

MDS 药物的技术进步，加上诊断技术的增强，正在推动市场的显着成长。例如，美国国家癌症研究所 (NCI) 指出，在过去 5 年中，使用新一代定序 (NGS) 进行 MDS 诊断的情况每年增加 20%。这项尖端技术可以精确定位与 MDS 相关的特定基因突变，从而促进量身定制的治疗计划。此外，《临床肿瘤学杂誌》上的一项研究强调，由于这些先进的工具，早期 MDS 诊断率提高了 30%。这种及时检测至关重要，可以采取干预措施来减缓疾病进展并提高患者治疗效果。因此，随着诊断方法的进步，对MDS药物的需求势将会增加。增强的诊断不仅​​可以提高治疗效果，还可以透过识别更多适合标靶治疗的患者来扩大市场。

MDS 药物产业根据药物类型、给药途径、药物、癌症类型、年龄层、最终用户和地区进行分类。

市面上的药物类型分为低甲基化药物、免疫疗法药物、抗贫血药物和血小板生成素受体激动剂。低甲基化药物领域预计将以 15 亿美元的收入领先，并在整个预测期内保持其主导地位。去甲基化药物，如阿扎胞苷 (Vidaza) 和地西他滨 (Dacogen)，是 MDS 治疗的基础，可显着提高存活率。例如，《柳叶刀肿瘤学》发表的临床研究表明，阿札胞苷比传统治疗方法可将总存活期延长多达 9.6 个月。鑑于其经过验证的功效和持续的创新，低甲基化药物将继续推动 MDS 药物市场。

市场将药物类型分为品牌药和仿製药。到 2032 年，品牌药物市场预计将达到 35 亿美元。这些药物旨在促进造血、减少输血依赖性并减缓疾病进展。例如，FDA 批准的 Vidaza（阿扎胞苷）和 Dacogen（地西他滨）是着名的低甲基化药物，凸显了品牌市场的成长轨迹。

美国骨髓增生异常综合症药物产业在 2023 年创造了 120 万美元的收入。促成美国领先的因素包括该疾病的高盛行率、最先进的医疗基础设施以及大量的医疗支出。就背景而言，白血病和淋巴瘤协会报告称，从 2015 年到 2019 年，美国平均每年新增 15,529 例 MDS 病例，同期病例总数为 77,646 例。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 药物开发的进展
    • 改进的诊断技术
    • 不断增强的疾病意识倡议
  • 产业陷阱与挑战
    • 治疗费用高
    • 来自替代疗法的竞争
• 成长潜力分析
• 监管环境
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021-2032

• 主要趋势
• 去甲基化药物
• 免疫治疗药物
  • 免疫调节药物
  • 免疫抑制药物
• 抗贫血药
• 血小板生成素受体激动剂

第 6 章：市场估计与预测：按管理途径，2021-2032 年

• 主要趋势
• 口服
• 注射用

第 7 章：市场估计与预测：按癌症类型，2021-2032 年

• 主要趋势
• 难治性贫血伴随原始细胞过多（RAEB）
• 难治性血球减少伴随多系发育不良 (RCMD)
• 难治性血球减少症伴随多谱系发育不良和环状铁粒幼细胞 (RCMD-RS)
• 其他癌症类型

第 8 章：市场估计与预测：按药物分类，2021-2032 年

• 主要趋势
• 品牌化
• 通用的

第 9 章：市场估计与预测：按年龄划分，2021-2032

• 主要趋势
• 80以上
• 70-79
• 60-69
• 50-59
• 40-49
• 40岁以下

第 10 章：市场估计与预测：按最终用户划分，2021-2032 年

• 主要趋势
• 医疗保健提供者
  • Hospitals
  • Specialty clinics
• 患者
• 其他最终用户

第 11 章：市场估计与预测：按地区划分，2021-2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 12 章：公司简介

• Amgen Inc.
• Astex Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company (Celgene Corporation)
• Cipla Limited
• Dr. Reddy's Laboratories Inc.
• Hikma Pharmaceuticals PLC
• Johnson and Johnson Services, Inc.
• Lupin Limited
• Otsuka America Pharmaceutical, Inc.
• Pfizer, Inc.
• Sandoz
• Shilpa Medicare Limited
• Sun Pharmaceutical Industries, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd

The Global Myelodysplastic Syndrome (MDS) Drugs Market was valued at USD 2.8 billion in 2023 and is projected to grow at an 8% CAGR from 2024 to 2032. This dynamic growth is primarily driven by the rising incidence of MDS, especially among the aging population, leading to heightened demand for effective treatments. For instance, the American Cancer Society reports that the U.S. sees approximately 10,000 new MDS cases diagnosed annually, predominantly in individuals over 60. Consequently, there's a notable uptick in the adoption of MDS drugs. Furthermore, advancements in diagnostic techniques have bolstered early MDS detection, paving the way for timely and effective treatments. This, in turn, amplifies the demand for MDS drugs.

Technological advancements in MDS drugs, coupled with enhanced diagnostic techniques, are propelling significant market growth. For instance, the National Cancer Institute (NCI) notes a 20% annual increase over the past five years in the use of next-generation sequencing (NGS) for MDS diagnosis. This cutting-edge technology pinpoints specific genetic mutations tied to MDS, facilitating tailored treatment plans. Moreover, a study in the Journal of Clinical Oncology highlighted a 30% boost in early MDS diagnosis rates thanks to these advanced tools. Such timely detection is paramount, allowing for interventions that can decelerate disease progression and elevate patient outcomes. Thus, as diagnostic methods advance, the demand for MDS drugs is poised to rise. Enhanced diagnostics not only elevate treatment efficacy but also expand the market by identifying more patients suited for targeted therapies.

The MDS drugs industry is classified based on drug type, route of administration, medication, cancer type, age group, end-user, and region.

The market categorizes drug types into hypomethylating agents, immune therapy drugs, anti-anemia, and thrombopoietin receptor agonists. The hypomethylating drugs segment is projected to lead with a revenue of USD 1.5 billion, maintaining its prominence throughout the forecast period. Hypomethylating agents, like azacitidine (Vidaza) and decitabine (Dacogen), are foundational to MDS therapy, significantly boosting survival rates. For instance, The Lancet Oncology published that clinical studies show azacitidine extends overall survival by up to 9.6 months over conventional treatments. Given their proven efficacy and ongoing innovations, hypomethylating agents will continue to drive the MDS drug market.

The market divides medication types into branded and generic drugs. The branded segment is on track to hit USD 3.5 billion by 2032. Central to MDS treatment, branded medications offer targeted therapies tailored to individual needs. These drugs aim to boost hematopoiesis, reduce transfusion dependence, and slow disease progression. For instance, FDA-approved Vidaza (azacitidine) and Dacogen (decitabine) are prominent hypomethylating agents, underscoring the branded market's growth trajectory.

The U.S. Myelodysplastic Syndrome Drugs Industry generated USD 1.2 million in revenue in 2023. This dominance is expected to continue growing during the analysis period. Factors contributing to the U.S.'s leadership include a high prevalence of the disease, a state-of-the-art healthcare infrastructure, and substantial healthcare spending. For context, The Leukemia and Lymphoma Society reported an average of 15,529 new MDS cases annually in the U.S. from 2015 to 2019, totaling 77,646 cases over that span.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancements in drug development
    • 3.2.1.2 Improved diagnostic techniques
    • 3.2.1.3 Growing disease awareness initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Competition from alternative treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021-2032 ($ Mn)

• 5.1 Key trends
• 5.2 Hypomethylating drugs
• 5.3 Immune therapy drugs
  • 5.3.1 Immunomodulatory drugs
  • 5.3.2 Immunosuppressive drugs
• 5.4 Antianemics drugs
• 5.5 Thrombopoietin receptor agonists

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021-2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021-2032 ($ Mn)

• 7.1 Key trends
• 7.2 Refractory anemia with excess blasts (RAEB)
• 7.3 Refractory cytopenia with multilineage dysplasia (RCMD)
• 7.4 Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)
• 7.5 Other cancer types

Chapter 8 Market Estimates and Forecast, By Medication, 2021-2032 ($ Mn)

• 8.1 Key trends
• 8.2 Branded
• 8.3 Generic

Chapter 9 Market Estimates and Forecast, By Age Group, 2021-2032 ($ Mn)

• 9.1 Key trends
• 9.2 Above 80
• 9.3 70-79
• 9.4 60-69
• 9.5 50-59
• 9.6 40-49
• 9.7 Below 40

Chapter 10 Market Estimates and Forecast, By End-user, 2021-2032 ($ Mn)

• 10.1 Key trends
• 10.2 Healthcare providers
  • 10.2.1 Hospitals
  • 10.2.2 Specialty clinics
• 10.3 Patients
• 10.4 Other end-users

Chapter 11 Market Estimates and Forecast, By Region, 2021-2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
  • 11.3.7 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
  • 11.5.4 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 South Africa
  • 11.6.3 UAE
  • 11.6.4 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Amgen Inc.
• 12.2 Astex Pharmaceuticals, Inc.
• 12.3 Bristol-Myers Squibb Company (Celgene Corporation)
• 12.4 Cipla Limited
• 12.5 Dr. Reddy's Laboratories Inc.
• 12.6 Hikma Pharmaceuticals PLC
• 12.7 Johnson and Johnson Services, Inc.
• 12.8 Lupin Limited
• 12.9 Otsuka America Pharmaceutical, Inc.
• 12.10 Pfizer, Inc.
• 12.11 Sandoz
• 12.12 Shilpa Medicare Limited
• 12.13 Sun Pharmaceutical Industries, Inc.
• 12.14 Takeda Pharmaceutical Company Limited
• 12.15 Teva Pharmaceutical Industries Ltd